{"organizations": [], "uuid": "259c74e2f18f9a22b6e35ac2e43e3ccadba8744b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "//sc.cnbcfm.com/applications/cnbc.com/staticcontent/img/cnbc_logo.gif", "site_section": "http://www.cnbc.com/id/10000027/page/8", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/01/08/globe-newswire-valeritas-reports-preliminary-full-year-and-fourth-quarter-2017-revenue-results.html", "country": "US", "domain_rank": 767, "title": "Valeritas Reports Preliminary Full Year and Fourth Quarter 2017 Revenue Results", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-08T15:30:00.000+02:00", "replies_count": 0, "uuid": "259c74e2f18f9a22b6e35ac2e43e3ccadba8744b"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/01/08/globe-newswire-valeritas-reports-preliminary-full-year-and-fourth-quarter-2017-revenue-results.html", "ord_in_thread": 0, "title": "Valeritas Reports Preliminary Full Year and Fourth Quarter 2017 Revenue Results", "locations": [], "entities": {"persons": [{"name": "valeritas", "sentiment": "none"}], "locations": [{"name": "n.j.", "sentiment": "none"}, {"name": "bridgewater", "sentiment": "none"}], "organizations": [{"name": "valeritas holdings", "sentiment": "negative"}, {"name": "valeritas holdings, inc", "sentiment": "none"}, {"name": "valeritas", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "BRIDGEWATER, N.J., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ:VLRX), a medical technology company which offers patients with type 2 diabetes V-Go® Wearable Insulin Delivery device , a simple, affordable, all-in-one insulin delivery option that is worn like a patch and can eliminate the need for taking multiple daily shots, today reported preliminary revenue results for the full year and fourth quarter ended December 31, 2017. Valeritas expects full year 2017 revenue to reach $20 million, in line with prior guidance. Fourth quarter revenue is expected to be approximately $5.6 million, which would represent growth of 16% year-over-year and 10% sequentially.\nThis financial information is preliminary and subject to completion of the company’s year-end financial reporting processes and audit. Valeritas intends to report its full year and fourth quarter 2017 financial results in February and will provide the anticipated report date in a subsequent press release.\nAbout Valeritas Holdings, Inc.\nValeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go® Wearable Insulin Delivery device, is a simple, affordable, all-in-one basal-bolus insulin delivery option for patients with type 2 diabetes that is worn like a patch and can eliminate the need for taking multiple daily shots. V-Go administers a continuous preset basal rate of insulin over 24 hours and it provides discreet on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of patients with type 2 diabetes. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Marlborough, Massachusetts.\nMore information is available at www.valeritas.com and our Twitter feed @Valeritas_US, www.twitter.com/Valeritas_US .\nForward-Looking Statements\nThis press release may contain forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to Valeritas technologies, business and product development plans and market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue Valeritas’ business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize the V-Go® Wearable Insulin Delivery device with limited resources, competition in the industry in which Valeritas operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and Valeritas assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents Valeritas files with the SEC available at www.sec.gov .\nInvestor Contacts:\nLynn Pieper Lewis or Greg Chodaczek\nGilmartin Group\n610-368-6505\nir@valeritas.com\nMedia Contact:\nKevin Knight\nKnight Marketing Communications, Ltd.\n(206) 451-4823\npr@valeritas.com\nSource:Valeritas, Inc.", "external_links": ["https://www.globenewswire.com/Tracker?data=zXJbY2sEiAoe1Iy9N9H24gvSQ-7DUfc-fFNB7YmqSSzm-O5uu3QhX_zrPhU4UKpOKYL4MsXi8pEs4HGoR6QSEQ==", "https://www.globenewswire.com/Tracker?data=Q_YbopYzMp1gg_qn1y76fn5pCAKMqInYurnHD7U9FoZa-TxKPOM0paS-9P99WGibpx35XTt834zlK-QKSJniN6no6VJelwWayN55p5B48PkD_Ey0V4UMsXpA7FqtET7i", "https://www.globenewswire.com/Tracker?data=0dMD9qnaZPpg5VkkskLvjRnZOnDnSUkGTPAi_VmVwRTKLi8gar96txGGLqsCCvYTxdouZFLnn8J0p2AzvxDi5yNxNRJf9d8m5gWlmKM51ZGplILOnB8GtaNAW9wioTg2", "https://www.globenewswire.com/NewsRoom/AttachmentNg/2874a8bf-ef94-4425-a367-98d954322ca9", "https://www.globenewswire.com/Tracker?data=PuhYJ5p_IhQT6PI0F_7pS6K1J4C72GVGb5HFHtUvS4oFi_fjgxsIfEymxdjF9DLxIo_FVIOL5B9a9z0RRBANlQ=="], "published": "2018-01-08T15:30:00.000+02:00", "crawled": "2018-01-08T19:21:19.020+02:00", "highlightTitle": ""}